Search research articles
Contact Us
Filters
Showing results (81-90 of 109) with videos related to
Page
of 11
Sort By:
Journal of Neurology
|
June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Journal of Neurology
|
July 31, 2025
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Current Therapeutic Research, Clinical and Experimental
|
December 8, 2025
Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure
Randal Goldberg, Lucy Norcliffe-Kaufmann, Horacio Kaufmann, et al.
International Journal of Environmental Research and Public Health
|
September 16, 2020
Characterization of Persistent Uncontrolled Asthma Symptoms in Community Members Exposed to World Trade Center Dust and Fumes
Joan Reibman, Caralee Caplan-Shaw, Yinxiang Wu, et al.
JIMD Reports
|
November 22, 2017
Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa
Kenneth I Berger, Barbara K Burton, Gregory D Lewis, et al.
Journal of Inherited Metabolic Disease
|
August 25, 2016
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
Christian J Hendriksz, Kenneth I Berger, Rossella Parini, et al.
European Journal of Internal Medicine
|
June 15, 2016
Unique medical issues in adult patients with mucopolysaccharidoses
John Mitchell, Kenneth I Berger, Andrea Borgo, et al.
American Journal of Medical Genetics. Part A
|
June 13, 2015
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study
Barbara K Burton, Kenneth I Berger, Gregory D Lewis, et al.
Journal of Occupational and Environmental Medicine
|
August 24, 2011
Lung pathologic findings in a local residential and working community exposed to World Trade Center dust, gas, and fumes
Caralee E Caplan-Shaw, Herman Yee, Linda Rogers, et al.
The Journal of Pediatrics
|
May 6, 2004
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)
James E Wraith, Lorne A Clarke, Michael Beck, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 109) with videos related to
Sort By:
Page
of 11
Journal of Neurology
|
June 19, 2024
Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Journal of Neurology
|
July 31, 2025
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry
Kenneth I Berger, Yin-Hsiu Chien, Alberto Dubrovsky, et al.
Current Therapeutic Research, Clinical and Experimental
|
December 8, 2025
Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure
Randal Goldberg, Lucy Norcliffe-Kaufmann, Horacio Kaufmann, et al.
International Journal of Environmental Research and Public Health
|
September 16, 2020
Characterization of Persistent Uncontrolled Asthma Symptoms in Community Members Exposed to World Trade Center Dust and Fumes
Joan Reibman, Caralee Caplan-Shaw, Yinxiang Wu, et al.
JIMD Reports
|
November 22, 2017
Cardiopulmonary Exercise Testing Reflects Improved Exercise Capacity in Response to Treatment in Morquio A Patients: Results of a 52-Week Pilot Study of Two Different Doses of Elosulfase Alfa
Kenneth I Berger, Barbara K Burton, Gregory D Lewis, et al.
Journal of Inherited Metabolic Disease
|
August 25, 2016
Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome
Christian J Hendriksz, Kenneth I Berger, Rossella Parini, et al.
European Journal of Internal Medicine
|
June 15, 2016
Unique medical issues in adult patients with mucopolysaccharidoses
John Mitchell, Kenneth I Berger, Andrea Borgo, et al.
American Journal of Medical Genetics. Part A
|
June 13, 2015
Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study
Barbara K Burton, Kenneth I Berger, Gregory D Lewis, et al.
Journal of Occupational and Environmental Medicine
|
August 24, 2011
Lung pathologic findings in a local residential and working community exposed to World Trade Center dust, gas, and fumes
Caralee E Caplan-Shaw, Herman Yee, Linda Rogers, et al.
The Journal of Pediatrics
|
May 6, 2004
Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)
James E Wraith, Lorne A Clarke, Michael Beck, et al.
Page
of 11